Acquisition momentum Nova Biomedical recently merged with Advanced Instruments in a $2.2B acquisition, signaling a significant expansion in bioprocessing and clinical diagnostics capabilities. This growth creates opportunities to cross-sell integrated analytics, instruments, and consumables to an enlarged global customer base across more than 100 countries.

Broad portfolio The company offers clinical diagnostics (blood gas, critical care, glucose analyzers), bioprocessing solutions (cell line development, real-time monitoring, process optimization), and veterinary diagnostics. This diversified mix enables multi-line selling, bundled solutions, and long-term account strategies with life sciences and healthcare providers.

Strong R&D Annual reinvestment in research and development supports a robust technology pipeline. For sales teams, this suggests upcoming innovations and new instrument offerings to position against competitors, as well as opportunities for upgrade cycles and pilot programs.

Global reach As the largest privately held IVD company in the U.S. with over 100 countries served, there is ample opportunity to expand into new markets and deepen penetration in high-growth regions, leveraging existing distribution networks and local support teams.

Growth drivers Recent product updates and launches by Advanced Instruments related to osmometers and automation indicate strong demand for performance, accuracy, and lab productivity enhancements. This creates sales angles around precision diagnostics, faster turnaround, and scalable bioprocessing workflows for life sciences and clinical labs.